Mereo BioPharma Group plc
MREO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 73.6% | – | – |
| R&D Expenses | $4 | $5 | $4 | $9 |
| G&A Expenses | $6 | $5 | $7 | $0 |
| SG&A Expenses | $6 | $5 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $11 | $11 | $15 |
| Operating Income | -$10 | -$10 | -$11 | -$15 |
| % Margin | – | -2,099.8% | – | – |
| Other Income/Exp. Net | $3 | -$4 | -$2 | $8 |
| Pre-Tax Income | -$7 | -$15 | -$13 | -$8 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$7 | -$15 | -$13 | -$7 |
| % Margin | – | -2,923.2% | – | – |
| EPS | -0.05 | -0.093 | -0.082 | -0.045 |
| % Growth | 45.9% | -12.8% | -82.2% | – |
| EPS Diluted | -0.05 | -0.093 | -0.082 | -0.045 |
| Weighted Avg Shares Out | 160 | 160 | 157 | 155 |
| Weighted Avg Shares Out Dil | 160 | 160 | 157 | 155 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | -$14 | -$12 | -$7 |
| % Margin | – | -2,858.8% | – | – |